A Phase 3 Study Assessing the Addition of Local Therapies to the Usual Chemotherapy for Limited Metastatic Colorectal Cancer: The ERASur Study


Full Title

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (A022101) (CIRB)


Limited metastatic colorectal cancer is cancer that has spread to no more than 4 parts of the body. The usual treatment for limited metastatic colorectal cancer is chemotherapy. In this study, researchers want to see if adding local therapies makes treatment work better. Local therapies are used to treat cancer only at specific sites.

The local therapies in this study include very focused radiation therapy called stereotactic ablative radiotherapy, surgery, and microwave ablation. With microwave ablation, a needle is temporarily inserted into a tumor and heat is used to destroy cancer cells. Together, these local therapies are called total ablative therapy (TAT).

If you join this study, you will be randomly assigned to one of two groups:

  • One group will get TAT plus the usual chemotherapy.
  • The other group will get the usual chemotherapy without TAT.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have limited metastatic colorectal cancer that does not contain genetic changes called microsatellite instability or BRAF V600E mutations.
  • Have received 4 to 6 months of prior chemotherapy for metastatic colorectal cancer.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Vonetta Williams’ office at 646-888-2668.




Phase III (phase 3)


ClinicalTrials.gov ID